Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Receivables (2018 - 2025)

UroGen Pharma (URGN) has disclosed Change in Receivables for 7 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 635.16% year-over-year to $13.4 million, compared with a TTM value of $12.8 million through Dec 2025, up 163.02%, and an annual FY2025 reading of $12.8 million, up 163.02% over the prior year.
  • Change in Receivables was $13.4 million for Q4 2025 at UroGen Pharma, up from $54000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $13.4 million in Q4 2025 and bottomed at -$2.7 million in Q3 2023.
  • Average Change in Receivables over 5 years is $1.3 million, with a median of $32500.0 recorded in 2025.
  • The sharpest move saw Change in Receivables tumbled 509.0% in 2024, then skyrocketed 635.16% in 2025.
  • Year by year, Change in Receivables stood at $3.9 million in 2021, then fell by 16.75% to $3.3 million in 2022, then dropped by 20.73% to $2.6 million in 2023, then plummeted by 196.3% to -$2.5 million in 2024, then surged by 635.16% to $13.4 million in 2025.
  • Business Quant data shows Change in Receivables for URGN at $13.4 million in Q4 2025, $54000.0 in Q3 2025, and $11000.0 in Q2 2025.